There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins)
in the treatment of hyperlipidemia were evaluated in 12 infants and children with
steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All
patients experienced a hypolipidemic response with a marked reduction in their total
cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels
(33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy
was well tolerated without clinical or laboratory adverse effects. In spite of a significant
hypolipidemic response to statin therapy there were no changes observed in the degree
of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure.
Long-term controlled studies with statin therapy are needed to further document or
negate their renoprotective role in refractory nephrotic syndrome.